Relapsed and refractory classical Hodgkin lymphoma: could virotherapy help solve the equation?

Classical Hodgkin lymphoma is a neoplastic hematological disease. Standard first-line therapy, including chemotherapy and radiotherapy, is curative in >85% of early-stage patients, with a 5-year survival rate of >95%. However, approximately 15% of patients have hard-to-treat lymphoma with poor outco...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Selma Addou, Clémentine Sarkozy, Julien Lazarovici, Stéphane Champiat, Aspasia Stamatoullas, Fabrice Jardin, Vincent Ribrag, Aurélien Marabelle, Jean-Marie Michot
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Taylor & Francis Group 2021-10-01
Serie:	Human Vaccines & Immunotherapeutics
Soggetti:	hodgkin lymphoma virotherapy oncolytic viruses epstein-barr virus
Accesso online:	http://dx.doi.org/10.1080/21645515.2021.1924521
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!